共 50 条
Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives
被引:6
|作者:
Hoepfner, Michael
[1
]
Schuppan, Detlef
[2
]
Scheruebl, Hans
[3
]
机构:
[1] Charite Univ Med Berlin, Inst Physiol, D-10967 Berlin, Germany
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Vivantes Netzwerk Gesundheit, Klinikum Urban, Klin Innere Med Gastroenterol & Gastrointestinale, D-10967 Berlin, Germany
关键词:
Growth factor receptor;
Biliary tract cancer;
Small molecule inhibitor;
Monoclonal antibody;
Innovative cancer treatment;
Sorafenib;
Bevacizumab;
Erlotinib;
D O I:
10.3748/wjg.14.7021
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
The limited efficacy of cytotoxic therapy for advanced biliary tract and gallbladder cancers emphasizes the need for novel and more effective medical treatment options. A better understanding of the specific biological features of these neoplasms led to the development of new targeted therapies, which take the abundant expression of several growth factors and cognate tyrosine kinase receptors into account. This review will briefly summarize the status and future perspectives of antiangiogenic and growth factor receptor-based pharmacological approaches for the treatment of biliary tract and gallbladder cancers. In view of multiple novel targeted approaches, the rationale for innovative therapies, such as combinations of growth factor (receptor)-targeting agents with cytotoxic drugs or with other novel anticancer drugs will be highlighted. (C) 2008 The WIG Press. All rights reserved.
引用
收藏
页码:7021 / 7032
页数:12
相关论文